The largest European oncology research center and two state-of-the-art hospitals. Institut Curie (IC) is a world-class Comprehensive Cancer Center with two cancer hospitals and a multidisciplinary cancer research centre combining research in biology, genetics, soft matter physics, organic and medicinal chemistry. Institut Curie hosts manyfacilities, including high-throughput sequencing (NGS), bioinformatics, high-performance computational cluster, as well as access to large clinical databases and sample collections. Institut Curie ‘s hospital group constitutes a major cancer center, treating more than 13000 cancer patients per year. Institut Curie is one of the most active French centers for early clinical trials in oncology and is a pioneer in precision medicine. IC incorporates a well renowned basic science campus for cancer research as well as a large translational science (and omics) platform. It is a referral center with a staff of > 3000 (>200 medical) persons involved in patient care, research and education as well as also having a role in cancer prevention. Its annual load is of > 12.000 new patients. IC runs a colposcopy clinic. IC has a complete electronic record since 2000 (430,000 records – more than 10 million documents) and structured databases, in particular for breast cancer patients (60,000 cases), with more than 10 years followup.
IC is certified by Inca (Institut national du cancer) to conduct early clinical trials. It has a technical platform controlling all aspects of clinical research, a clinical database, and a department of statistics and of epidemiology. Backed by an international renowned research center, IC deploys a project of automatic structuring and data integration including omics, clinical and imaging data. IC has a bioinformatics platform (Dr. Emmanuel Barrillot) ensuring the development and setup of automatic pipelines for high-throughput data analysis, and a molecular platform (labelled in 2006 by INCa) and coordinated by Dr Olivier Delattre and Dr Ivan Bièche tested more than 3,000 patients in 2013 for molecular predictive tests. This platform generates at a routine bases molecular data that needs to be bridged to the patient’s clinical record. Multidisciplinary research projects including the SHIVA trial (Le Tourneau et al. 2015), as well as the routine molecular biology board and molecular diagnosis and prognosis data from pediatric cancers continuously enrich IC databases.